Ablation or surgical excision is the typical treatment of anal high-grade squamous intraepithelial lesions (HSIL). Recurrences are common due to the persistence of underlying human papillomavirus (HPV) infection. Additional well-tolerated and effective non-surgical options for HPV-associated anal disease are needed. This 3+3 dose escalation Phase I clinical trial evaluated the safety and tolerability of artesunate suppositories in the treatment of patients with biopsy-proven HSIL. The maximal tolerated dose was 400 mg, administered in 3 cycles. All adverse events associated with the use 200- and 400-mg artesunate suppositories were Grade 1. At the 600-mg dose, patients experienced clinically significant nausea. Artesunate suppositories are a safe treatment option for anal HSIL.
Objective: We sought to examine abnormal parathyroid glands for the presence of stem cells. Summary Background Data: Cancer stem cells have been identified in cancers from a variety of tissues as a CD44+/CD24− cell population. We hypothesize that stem cells (SC) may also be involved in the pathogenesis of benign clonal expansion characteristic of hyperparathyroidism (HPT). Methods: Under institutional review board approval, parathyroid tissue was obtained from 20 patients with HPT and analyzed by fluorescence-activated cell sorting (FACS) for the CD44+/CD24− cell population. Immunohistochemistry (IHC) with CD44 antibody was correlated with FACS results. Results: Parathyroid tissue was obtained for FACS analysis from 25 enlarged parathyroid glands from 20 patients, 17 with primary HPT, and 3 with secondary HPT. The average percent of SC defined as CD44+/CD24− population was 10.93% for enlarged parathyroid glands. IHC using CD44 antibody was performed on 27 abnormal parathyroid glands and 7 normal parathyroid gland biopsies from the same patients. Although IHC was not as sensitive as FACS, comparison of IHC and FACS results for 24 abnormal glands gave a correlation coefficient of 0.52, which was statistically significant (P = 0.01, Spearman rank). By IHC, 13 of 27 abnormal glands stained 1+ to 3+ (average, 0.93) compared with no CD44 staining in normal glands, which was statistically different (mean IHC of 0 vs. 0.93, P = 0.03, Wilcoxon). Conclusions: These novel findings demonstrate expansion of a resident cell population that expresses SC markers in abnormal parathyroid glands from patients with HPT. Our results suggest that clonal expansion of a resident SC population occurs in the pathogenesis not only of cancer, but also in benign parathyroid tumors occurring in HPT.
Aim: Monitoring of tumor biology provides pivotal information for suitable therapy. Circulating tumor cells (CTCs) released into the blood stream from primary tumor and metastases may reflect current tumor status. The ClearCell FX system (Clearbridge Biomedics, Singapore), which uses a label-free inertial microfluidics approach based on biomechanical properties, is able to capture CTCs independent of EpCAM expression. We investigated the tumor biology by performing genomic profiling of CTCs using next-generation sequencing (NGS). Methods: Patients with advanced gastric and colorectal cancer were enrolled in this study. We collected 10mL of blood from each patient. CTCs were extracted by using the Clearcell FX system. DNA was prepared immediately after isolation, after a week's culture with RepCellTM (CellSeed) which was a temperature-responsive cell cultureware. Whole genome amplification (WGA) was performed by using REPLI-g Single Cell Kit (Qiagen), and NGS was performed by using Ion Ampliseq (LifeTechnology). Cells were enumerated using cytokeratin staining and immunocytochemical analysis. At the same time, we prepared DNA not only from peripheral blood mononuclear cells but also from plasma (cell-free DNA). Results: 8 patients were enrolled; 6 had colorectal cancer and 2 had gastric cancer. Median of CTC count was 6/mL (ranges 3 to 14). On the other hand, the number of CTCs collected by CellSearch ranged from 0 to 1/7.5mL. In these 8 cases, either right after isolation or after 1 week of culture, DNA derived from CTCs was successfully prepared by WGA. NGS was successfully performed with WGA treated DNA from CTCs and related materials. Conclusions: By using ClearCell FX System's label-free technology, we were able to capture a larger number of CTCs from patients with gastric and colorectal cancer than with using the CellSearch system. NGS from CTCs and related materials can be performed successfully. Disclosure: A. Kakimoto: I am a employee of SRL Inc.; T. Sakuma: I am a employee of Mitsui Knowledge Industry Co and Ltd.; S. Fang: I am a employee of Clearbridge Accelarator; A. Wu: I am a employee of Clearbridge Bio Medics; C.T. Lim: I have stock of Clearbridge Biomedics Pte Ltd. All other authors have declared no conflicts of interest.
Background: Anal cancer screening has allowed for the diagnosis of early-stage anal cancers; however, guidelines for the treatment of early anal cancers remain mixed given the scarcity of clinical trials and data. Management ranges from chemoradiation therapy to local surgical excision. Methods: This paper’s objective is to clarify the definition of early anal cancer and its management. Approval for this systematic review was obtained through PROSPERO [CRD42022304327]. Three independent reviewers screened the studies and performed data analysis, with conflicts resolved by a fourth reviewer. All information is presented according to the Preferred Reporting Item for Systematic Reviews and Meta-Analysis (PRISMA). The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) criteria were used to assess the certainty of the evidence. Results: The MEDLINE, EMBASE and Cochrane databases were queried with 628 articles screened. A total of 15 articles were selected for inclusion. Early anal cancer was most often defined as T1-2N0M0 anal cancer but also included Superficially Invasive Squamous Cell Carcinoma (SISCCA). There were various treatments assessed for outcomes including local excision, chemoradiation, and radiation. The studies reported overall survival, cancer-specific survival, recurrence-free survival, and/or colostomy-free survival, leading to significant heterogeneity amongst the studies. No meta-analysis was possible. Conclusions: Poor-quality studies exist for the evaluation of the most effective treatment modality for early anal cancer. Surgical excision alone with adequate margins has equivocal results, but data is poor. Chemoradiation is successful but may be overtreatment. Randomized controlled studies are needed, as screening will result in earlier anal cancer diagnoses.